AMRN News 1.69 06/30/2014 04:26:02 Amarin Corporation Plc (A

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarin Corporation Plc (AMRN) 1.69 $AMRN

Rick Harrison of Television's "Pawn Stars®" Discusses His Revelations on Seeking Treatment for His Very High Triglycerides in National Awareness Campaign
PR Newswire - Wed Jun 25, 5:30AM CDT
Amarin Corporation, plc (Nasdaq: AMRN), today announced a national partnership with Rick Harrison, star of the hit television show "Pawn Stars®," in launching Lower My Trigs(TM), a national awareness campaign about seeking treatment for very high triglycerides (VHTG) (> 500 mg/dL), a problem faced by up to four million Americans. Amarin has engaged Harrison as a spokesperson for the campaign to inform patients and family members, their physicians and other health care professionals about the health risks of very high triglycerides and the importance of patients discussing available treatment options with their physician.

Of These 3 Battleground Biotech Stocks, 1 Is a Buy
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 9:26AM CDT
The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable. First up: Amarin has a drug on the market, but unfortunately its fish oil Vascepa has struggled to gain much...

Biotech 101: Off-Label Prescriptions
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 8:21PM CDT
When the Food and Drug Administration approves a drug, it's given a label, although there's no sticky stuff on the back and it's not attached to the bottle. Drug labels are multipage documents that list everything from the chemical description of the...

Amarin Up 5.2%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Thu Jun 19, 10:38AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 5.2% to $1.63 on 1.4x average daily volume. Thus far today, Amarin has traded 2.2 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.2%) and outperformed the S&P 500 (5.2% to the S&P's -0.1%) during today's trading.

Stock Watchout on Biotech Industry -- Research on Isis Pharma, Pharmacyclics, Amarin, and Prana Biotechnology
PR Newswire - Wed Jun 11, 6:10AM CDT
The US markets on Tuesday, June 10, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,945.92, up 0.02% and the NASDAQ Composite closed at 4,338.00, up 0.04%. The S&P 500 finished the session 0.02% lower at 1,950.79. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 692.83, up 0.21%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Amarin Corp. PLC (NASDAQ: AMRN) and Prana Biotechnology Ltd (NASDAQ: PRAN). Free technical research on ISIS, PCYC, AMRN and PRAN can be downloaded upon signing up at:

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)
Marketwire - Wed Jun 11, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the publication of a retrospective analysis of patient cases that examined the effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza® (omega-3-acid ethyl esters) capsules, a mixture of omega fatty acids, to Vascepa® (icosapent ethyl) capsules, the only pure-EPA prescription omega-3 product, to potentially achieve better outcomes in triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels.1 During the studied period, most of the 14 patients switched to Vascepa experienced reductions in levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C).

Amarin to Present at the Goldman Sachs 2014 Global Healthcare Conference
Marketwire - Thu Jun 05, 2:15AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Goldman Sachs 2014 Global Healthcare Conference on Wednesday, June 11, 2014, at 3:20 p.m. PT.

Amarin to Present at the Jefferies 2014 Global Healthcare Conference
Marketwire - Thu May 29, 7:03AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014, at 8:00 a.m. ET.

High Triglyceridemia Therapeutics Pipeline Review 2014 - 16 Companies & 19 Drug Profiles
M2 - Tue May 20, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bkl7cl/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Tekmira Pharmaceuticals Corp. - Actavis plc - Isis Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Amarin Corporation plc - Alnylam Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cardax Pharmaceuticals, Inc. - Essentialis, Inc. - Epax AS - Pharmena SA - FORMAC Pharmaceuticals N.V. - Omthera Pharmaceuticals, Inc. - Poxel SA - Acasti Pharma Inc. Drug Profiles - icosapent ethyl - omega-3-carboxylic acids - diazoxide CR - AKR-963 - TRIA-662 - ISIS-APOCIIIRx - NKPL-66 - pradigastat sodium - CAT-2003 - fenofibrate - bezafibrate ER - CDX-085 - CAT-2000 Series - AS-1708727 - MAT-9001 - Drug For Hypertriglyceridemia - ALN-ANG - Small Molecule Farnesoid X Receptor Agonist for Gastrointestinal, Metabolic and Cardiovascular Diseases - Peptides for Dyslipidemic and Vascular Disorders For more information visit http://www.researchandmarkets.com/research/bkl7cl/high

AstraZeneca's Fishy FDA Approval
Brian Orelli, The Motley Fool - Motley Fool - Mon May 19, 5:28PM CDT
The Food and Drug Administration recently approved AstraZeneca 's Epanova, adding it to the growing list of omega-3 fish oil drugs that includes GlaxoSmithKline 's Lovaza and Amarin 's Vascepa. In the following video, senior biotech...

Ligand-AstraZeneca Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 5:00PM CDT
Ligand Pharmaceuticals Inc. (LGND) and AstraZeneca signed a licensing and research deal.

Technical Pulse on Active Equities -- Research on Amarin, Abbott Laboratories, Apple, and T-MobileUS
PR Newswire - Fri May 16, 9:23AM CDT
The trading session on Thursday, May 15, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,446.81, down 1.01% and the NASDAQ Composite closed at 4,069.29, down 0.76%. The S&P 500 finished the day 0.94% lower at 1,870.85. The losses were broad based as nine out of ten sectors finished on a negative note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Amarin Corp. PLC (NASDAQ: AMRN), Abbott Laboratories (NYSE: ABT), Apple Inc. (NASDAQ: AAPL) and T-Mobile US Inc. (NYSE: TMUS). Free technical research on AMRN, ABT, AAPL and TMUS can be downloaded upon signing up at:

Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Thu May 15, 1:37PM CDT
Amarin (AMRN) is down big after announcing private exchange transaction of outstanding senior notes.

Why Amarin Corporation PLC Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Thu May 15, 12:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin , a biopharmaceutical company...

Amarin Down 8.6%, Shares Slide into the Red (AMRN)
Comtex SmarTrend(R) - Thu May 15, 10:09AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 8.6% to $1.39 on 1.4x average daily volume. Thus far today, Amarin has traded 2.4 million shares, vs. average volume of 1.7 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.9%) and underperformed the S&P 500 (-8.6% to the S&P's -1.0%) during today's trading.

Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes
GlobeNewswire - Thu May 15, 5:19AM CDT
Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" , announced today that it and its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer" , have entered into separate, privately negotiated exchange agreements with certain holders of its outstanding 3.50% Exchangeable Senior Notes due 2032 issued on January 9, 2012 (the "2012 Notes" pursuant to which the Issuer will exchange $118.734 million in aggregate principal amount of the 2012 Notes for $118.734 million in aggregate principal amount of new 3.50% May 2014 Exchangeable Senior Notes due 2032 (the "2014 Notes" . Following the closing of these transactions, $31.266 million in aggregate principal amount of the 2012 Notes will remain outstanding with terms unchanged. The 2014 Notes will be exchangeable into American Depositary Shares of Amarin ("ADSs" at the option of the holders at an initial exchange rate of 384.6154 ADSs per $1,000 principal amount of 2014 Notes (equivalent to an initial exchange price of approximately $2.60 per ADS), subject to adjustment in certain circumstances. The exchange is expected to close on May 20, 2014, subject to customary closing conditions.

Downgrade Alert for Amarin (AMRN)
Comtex SmarTrend(R) - Mon May 12, 7:11AM CDT
Amarin (NASDAQ:AMRN) was downgraded from Buy to Neutral at Citigroup today. The stock closed yesterday at $1.51 on volume of 2.4 million shares, above average daily volume of 1.8 million. Amarin Corporation PLC is a clinical-stage biopharmaceutical company. The Company researches, develops, and commercializes drugs for the treatment of hypertriglyceridemia, central nervous system disorders, and cardiovascular diseases.

Health Care Stocks to Watch Today: Amarin Corporation plc, Jazz Pharmaceuticals, and Vanda Pharmaceu
George Budwell, The Motley Fool - Motley Fool - Fri May 09, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Amarin ,  Jazz Pharmaceuticals and  Vanda Pharmaceuticals .   Amarin reports first-quarter earnings The much-maligned biotech Amarin reported...

Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations
GlobeNewswire - Fri May 09, 6:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2014, and provided an update on company operations.

Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
GlobeNewswire - Mon May 05, 8:41AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2014 financial results and provide an operational update on Friday, May 9, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's first quarter 2014 financial results earlier that day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 164

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

New York Court Upholds Healthcare Rights for Retirees

Updated Category News Views 94

New York Court of Appeals Decision on Retiree Healthcare Rights In a landmark ruling, the New York Court of Appeals determined that the city is required to cover the total cost of the health insurance plans chosen by its retirees. This decision represents a significant win for over 250,000 retired workers and their families seeking to maintain their healthcare benefits....

Continue Reading
Corning's Strategic Path Amid AI Trends and Market Challenges

Updated Category News Views 1824

Corning Incorporated (NYSE: GLW) hit a crossroads back in 2024 as it tried to balance rising AI trends with challenges lurking in traditional markets. Renowned for its expertise in materials science, particularly specialty glass and optical physics, Corning was looking to leverage these trends while facing stiff competition and economic uncertainties. Quarterly...

Continue Reading
Innovating the Future: The Inaugural Global Quantum Forum

Updated Category News Views 274

Inaugural Global Quantum Forum Set to Launch During TechChicago Week The upcoming Global Quantum Forum promises to be a landmark event for the quantum industry, coinciding with the much-anticipated TechChicago Week. This two-day conference is positioned to take place in an exciting environment where innovation meets collaboration. With over 70 distinguished speakers,...

Continue Reading
Oil Prices React to US Supply and Rising Geopolitical Risks

Updated Category News Views 83

Oil Market Overview: Supply Dynamics and Geopolitical Tensions As oil prices faced a dip recently, analysts found that U.S. supply levels play a significant role in shaping market trends. The weekly report reflecting increased U.S. crude and gasoline stocks was a key factor influencing the downturn. Insights on Current Oil Price Performance Brent crude futures for January...

Continue Reading
Senator McConnell's Recent Stock Purchase Insights and Implications

Updated Category News Views 160

Insights into Senator McConnell's Stock Purchase Recently, it has come to public attention that Senator A. Mitchell McConnell, Jr. has made a notable financial move by purchasing stock in Wells Fargo (NYSE: WFC). This purchase, reported to be valued between $1,001 and $15,000, is part of a pattern of trading activity that might have implications for investors and stock...

Continue Reading